Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib for Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
2023-504539-42-00Phase 2Completed
- Sponsor
- Innovaderm Research
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Abrocitinib with Placebo (2 arms). Primary endpoint: Percent change from baseline in hand mTLSS at Week 16. Started Oct 2024; status: completed.
02
Drugs
abrocitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2023-504539-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504539-42-00.